Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,263 stopped studies mapped to Lung Carcinoma and descendants · 91% state a reason
Over the 1,263 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch…(REFIT-MSS) | Phase 2 | withdrawn | Oct 17, 2022 | Translational Research in Oncology | Study never started/ will not proceed. | Other (stated, no rule matched) |
| NCT04625699 | Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment | Phase 2 | withdrawn | Nov 12, 2020 | Catherine Shu | Contract was never finalized. | Other (stated, no rule matched) |
| NCT03637803 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | Phase 1 / Phase 2 | terminated | Aug 20, 2018 | 4D pharma plc | Sponsor insolvency | Other (stated, no rule matched) |
| NCT03233724 | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated… | Phase 1 / Phase 2 | terminated | Jul 31, 2017 | National Cancer Institute (NCI) | Study terminated due to drug supply issues. | Drug supply |
| NCT04849273 | A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+… | Phase 1 | terminated | Apr 19, 2021 | Turning Point Therapeutics, Inc. | Adverse change in the risk/benefit. | Safety / toxicity |
| NCT02607423 | Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage… | Phase 2 | withdrawn | Nov 18, 2015 | ECOG-ACRIN Cancer Research Group | The study failed to meet its accrual targets. | Enrollment / accrual |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in… | Phase 3 | terminated | Jul 27, 2009 | SWOG Cancer Research Network | terminated at pre-planned futility analysis | Efficacy / futility |
| NCT02382406 | Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC | Phase 1 / Phase 2 | terminated | Mar 6, 2015 | Nisha Mohindra, MD | The study was completed. It was fully accrued. | Enrollment / accrual |
| NCT03275597 | Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung… | Phase 1 | terminated | Sep 7, 2017 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT02961283 | Study of ASN003 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Nov 10, 2016 | Asana BioSciences | reformulation | Other (stated, no rule matched) |
| NCT01912625 | Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With… | Phase 1 | terminated | Jul 31, 2013 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03488472 | Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain(RAD 1704) | N/A | terminated | Apr 5, 2018 | Drexell Hunter Boggs | This feasibility study only accrued one patient since site activation. We believe that the primary… | Enrollment / accrual |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | Phase 1 | terminated | Mar 3, 2015 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT03802058 | Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer | Phase 2 | terminated | Jan 14, 2019 | Wuhan University | The study was halted because enrollment was too slow | Enrollment / accrual |
| NCT01971489 | Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced… | Phase 1 | withdrawn | Oct 29, 2013 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT03632369 | Hyperpolarized Noble Gas MRI Detection of Radiation-Induced Lung Injury | — | withdrawn | Aug 15, 2018 | Thunder Bay Regional Health Research Institute | No participants were enrolled and no data was collected for the study | Enrollment / accrual |
| NCT05001724 | KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure… | Phase 2 / Phase 3 | terminated | Aug 12, 2021 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Because the efficacy data did not meet expectations, the sponsor decided to terminate the study. | Efficacy / futility |
| NCT04590781 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or… | Phase 1 / Phase 2 | terminated | Oct 19, 2020 | Xencor, Inc. | The study has been terminated early by the sponsor due to business decision. | Sponsor / business decision |
| NCT04863248 | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic…(PRESERVE 4) | Phase 2 | terminated | Apr 28, 2021 | G1 Therapeutics, Inc. | Treatment paradigm in second- and third-line NSCLC is shifting away from docetaxel, the backbone… | Other (stated, no rule matched) |
| NCT03406715 | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With… | Phase 2 | terminated | Jan 23, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Sponsor closed study | Other (stated, no rule matched) |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | Phase 1 | terminated | Aug 2, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05212922 | A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC…(YH001) | Phase 2 | withdrawn | Jan 28, 2022 | Eucure (Beijing) Biopharma Co., Ltd | Sponsor Decision | Sponsor / business decision |
| NCT02771626 | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal… | Phase 1 / Phase 2 | terminated | May 13, 2016 | Calithera Biosciences, Inc | lack of efficacy | Efficacy / futility |
| NCT03030131 | Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer(IONESCO) | Phase 2 | terminated | Jan 24, 2017 | Intergroupe Francophone de Cancerologie Thoracique | Definitive discontinuation according to safety monitoring of death from the 46th patient onwards. | Safety / toxicity |
| NCT04698681 | NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE… | — | terminated | Jan 7, 2021 | Calithera Biosciences, Inc | Lack of Clinical Benefit | Efficacy / futility |
| NCT03138889 | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or…(PROPEL) | Phase 1 / Phase 2 | terminated | May 3, 2017 | Nektar Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT05693090 | Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer | Phase 1 | withdrawn | Jan 20, 2023 | Kura Oncology, Inc. | This study was withdrawn due to a strategic business decision; no patients were enrolled. | Enrollment / accrual |
| NCT03838848 | KN046 in Patients With Advanced Non-small Cell Lung Cancer | Phase 2 | terminated | Feb 12, 2019 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Cohort A,B,C end enrollments. Cohort D and E were considered to have no significant clinical… | Enrollment / accrual |
| NCT04650490 | SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases…(STICk-IM-NSCLC) | Phase 2 | withdrawn | Dec 2, 2020 | Duke University | failure to enroll | Enrollment / accrual |
| NCT03713944 | Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and… | Phase 2 | terminated | Oct 22, 2018 | Nasser Hanna | Extreme toxicity, thromboembolic events | Safety / toxicity |
| NCT03265080 | A Study of ADXS-NEO Expressing Personalized Tumor Antigens(NEO) | Phase 1 | terminated | Aug 29, 2017 | Advaxis, Inc. | Business decision | Sponsor / business decision |
| NCT04438902 | Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression… | Phase 2 | terminated | Jun 19, 2020 | First Affiliated Hospital of Zhejiang University | Many patients can't tolerate the combination treatment due to adverse events. | Safety / toxicity |
| NCT04622072 | XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or… | Phase 1 | terminated | Nov 9, 2020 | Sihuan Pharmaceutical Holdings Group Ltd. | Strategic considerations | Sponsor / business decision |
| NCT03707925 | Bronchoscopic Laser Ablation of Peripheral Lung Tumors | N/A | terminated | Oct 16, 2018 | M.D. Anderson Cancer Center | Very slow accrual rate | Enrollment / accrual |
| NCT02963090 | Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | Phase 2 | terminated | Nov 15, 2016 | Alliance Foundation Trials, LLC. | Lack of enrollment | Enrollment / accrual |
| NCT03656627 | Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing… | Phase 1 | terminated | Sep 4, 2018 | Alliance Foundation Trials, LLC. | low accrual | Enrollment / accrual |
| NCT03663166 | Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage… | Phase 1 / Phase 2 | terminated | Sep 10, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Increased SAE occurrence per PI | Other (stated, no rule matched) |
| NCT02834247 | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid… | Phase 1 | terminated | Jul 15, 2016 | Calithera Biosciences, Inc | Insufficient efficacy of drug; no safety concern | Safety / toxicity |
| NCT03599518 | DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor… | Phase 1 | terminated | Jul 26, 2018 | Daiichi Sankyo Co., Ltd. | This study was terminated based on a business decision by the Sponsor. | Sponsor / business decision |
| NCT02513667 | Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung… | Phase 2 | terminated | Jul 31, 2015 | University of Texas Southwestern Medical Center | The study was terminated after UTSW was informed by Novartis that further support for the study… | Other (stated, no rule matched) |
| NCT02706626 | Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors | Phase 2 | terminated | Mar 11, 2016 | Criterium, Inc. | Did not meet enrollment objectives. | Enrollment / accrual |
| NCT04297748 | Bioimaging Study of 89Zr-M7824 in NSCLC | Phase 1 / Phase 2 | terminated | Mar 5, 2020 | Olivia Newton-John Cancer Research Institute | Efficacy finding | Efficacy / futility |
| NCT02454842 | Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor…(TH-4000) | Phase 2 | terminated | May 27, 2015 | Rain Oncology Inc | Lack of efficacy | Efficacy / futility |
| NCT03455556 | Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small… | Phase 1 | terminated | Mar 6, 2018 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT03087448 | Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer… | Phase 1 | terminated | Mar 22, 2017 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT04941365 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(SERPENTINE) | N/A | withdrawn | Jun 28, 2021 | Institut du Cancer de Montpellier - Val d'Aurelle | please refer to NCT05621837 | Other (stated, no rule matched) |
| NCT02607813 | Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway… | Phase 1 | terminated | Nov 18, 2015 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT05393635 | ITIL-168 in Advanced Solid Tumors(DELTA-2) | Phase 1 | withdrawn | May 26, 2022 | Instil Bio | business decision | Sponsor / business decision |
| NCT02987998 | Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in… | Phase 1 | terminated | Dec 9, 2016 | Nathan Pennell, MD, PhD | higher than expected rate of toxicity \& unrealistic timeline to complete trial under company's… | Safety / toxicity |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | Phase 1 / Phase 2 | terminated | Feb 2, 2022 | Rubius Therapeutics | The Sponsor terminated study after dosing 2 dose groups (7 pts) and closed trial on 11/30/22.… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 7, 2023source: clinicaltrials